Piers E M Patten

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of eerstelijns ibrutinib treatment for CLL/SLL.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with ...

CLL-therapie gestuurd door MRD: overzicht

Ibrutinib-rituximab versus FCR bij eerder onbehandelde CLL: E1912 vijfjaars definitief